{"public_id":"cl_7b77c0dab1ba732f10d51306f23ad3a5","status":"active","superseded_by_public_id":null,"corpus_id":10389450,"text":"The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years.","confidence":0.98,"paper":{"corpus_id":10389450,"title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance.","url":"https://sah.borca.ai/papers/10389450"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.98,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_1e73c443ee4720bfe6b16d7759f762bd","name":"cumulative probability of progression","description":"The estimated chance that MGUS advances to a more serious disorder over time.","types":["outcome measure"],"url":"https://sah.borca.ai/concepts/co_1e73c443ee4720bfe6b16d7759f762bd"},{"public_id":"co_8e536886c7f99d2174ed588c0a184caf","name":"monoclonal gammopathy of undetermined significance","description":"A plasma-cell disorder characterized by the presence of a monoclonal protein without overt malignant disease.","types":["condition"],"url":"https://sah.borca.ai/concepts/co_8e536886c7f99d2174ed588c0a184caf"},{"public_id":"co_eb9cd94a79316adb4b3757b08801dd60","name":"follow-up","description":"The period during which patients were observed for progression outcomes.","types":["study period"],"url":"https://sah.borca.ai/concepts/co_eb9cd94a79316adb4b3757b08801dd60"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_7b77c0dab1ba732f10d51306f23ad3a5"}